The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Donepezil and Memantine for Moderate-to Severe Alzheimers Disease
NEJM 366:893-903,957, Howard,R.,et al, 2012
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Donepezil Preserves Cognition and Global Function in Patients With Severe Alzheimer Disease
Neurol 69:459-469, Black,S.E.,et al, 2007
Donepezil for the Treatment of Agitation in Alzheimers Disease
NEJM 357:1382-1392,1441, Howard,R.J.,et al, 2007
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric symptoms and Functional Impairment in Alzheimer Disease
JAMA 289:210-216, Trinh,N.,et al, 2003
Acetylcholinesterase Inhibitors for Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease
Stroke 34:584-586, Bowler,J.V., 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Drug Treatment of Alzheimer's Disease, Raise Clinical and Ethical Problems
BMJ 314:693-694, Kelley,C.A.,et al, 1997
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Efficacy of Tacrine and Lecthin in Mild to Moderate Alzheimer's Disease:Double Blind Trial
BMJ 308:879-883, Maltby,N.,et al, 1994
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease
NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
Tetrahydroaminoacridine (THA) in Alzheimer's Disease, Not Ready for Routine Use
BMJ 298:845-846, Graham,T.R.&Lewis,C.T., 1989
Long-Term Administration of Oral Physostigmine in Alzheimer's Disease
Neurol 38:1837-1841, Stern,Y.,et al, 1988
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
NEJM 315:1241-1245, Summers,W.K.,et al, 1986
Memory Enhancement with Oral Physostigmine in Alzheimer's Disease
NEJM 308:720-721, Thal,L.J.,et al, 1983
Enhancement Of Memory By Physostigmine
NEJM 301:946, Davis,K.L.,et al, 1979